Stocks in Focus on April 12: TCS, Infosys, Pharma Stocks, Solara Active Pharma to Balrampur Chini; here are the 5 Newsmakers of the Day

Domestic equity markets snapped the three-day winning stream and trader range-bound in the negativity territory on Friday, April 9, 2021. The markets failed to hold the gains amid mixed global cues and a record surge in Covid-19 cases in India which is coupled with reports of a vaccine supply crunch. The S&P BSE Sensex declined 154.89 points or 0.31 per cent and close at 49,591.32. The Nifty 50 index lost 38.95 points or 0.26 per cent to settle at 14,834.85. But certain stocks came in the news after the market was closed. These stocks can impact the indices when it reopens on Monday, April 12, 2021. List of such five stocks:

See Zee Business Live TV Streaming Below:

TCS Results Today + Infosys Buyback

TCS: Tata Consultancy Services (TCS) is scheduled to declare its financial results for the quarter ended March 31, 2021, and FY21. Besides, the board of the IT giant will take a call on the final dividend. 
Infosys: The board of Infosys will consider a proposal for buyback of fully paid-up equity shares of the Company at its meeting to be held on April 14, 2021. Earlier, the board was supposed to consider and approve the results for the quarter ended March 31, 2021, as well as final dividends. 

Cadila/ Cipla/ Jubilant Pharmova/ Dr. Reddy’s: Amid a surge in COVID-19 cases in the country, the government has prohibited the exports of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) till the situation improves. 

Solara Active Pharma + Natco Pharma 

Solara Active Pharma: Solara Active Pharma Sciences Limited has announced that its board of directors has approved the amalgamation of Aurore Life Sciences along with its subsidiaries Empyrean and Hydra with Solara. The combination creates the second-largest pure-play API/CRAMs company of scale with a strong presence. After the merger, the shareholders of Aurore Life Sciences would have a 27% stake in Solara Active Pharma Sciences. Solara will hold a 67% stake in Aurore Pharmaceuticals Private Limited.
Natco Pharma: It announced on Saturday that its marketing and distribution partner Alvogen Pine Brook LLC, has received tentative approval for our Abbreviated New Drug Application (ANDA) for Ibrutinib Tablets 560mg, 420mg, 280mg and 140mg strengths (generic for IMBRUVICA), from the U.S. Food and Drug Administration (USFDA). As per industry sales data, IMBRUVICA® (Tablet and Capsule dosage forms) had generated annual sales of $370 crore during the twelve months ending December 2020 in the US market. 

Ambuja Cement + Balrampur Chini

Ambuja Cements: Updates from the 38th Annual General Meeting (“AGM”) of the Company was held on Friday. The company says that it is on track to reach the cement capacity of 50 MTPA. Its upcoming facility in Marwar Mundwa, Rajasthan will enhance clinker capacity by 3 MTPA and help improve cement sales by 5 MTPA, contributing to the long-term strategy of capacity expansion. The company will invest Rs. 2,350 crore in this Greenfield integrated plant, which will commence operations by Q3 2021.
Balrampur Chini: The company on Saturday announced that its board has approved the revised CapEx of Rs. 425 crores for the 320 KLPD (Kilo litre per day) Distillery Plant which was earlier approved at Rs. 320 crores by the Board in November 2020. The increase in CapEx to the tune of Rs. 105 crores are mainly owing to the inclusion of 20 KLPD ENA plant, within the overall 320 KLPD distillery plant, higher storage capacity for raw material and finished goods and a sharp rise in steel prices. Besides, the credit rating agency ICRA Limited has re-affirmed the Credit Ratings for both long-term and short-term as [ICRA]AA and [ICRA]A1 + respectively. The outlook on the long-term rating has been revised to positive from stable. 

Timken India + Saint Gobain 

Timken India:  Tricot Investments sold 11.20 lakh shares (1.49%) at Rs 1,360 per share. HDFC Mutual Fund bought 9.20 lakh shares (1.22%) at Rs 1,360 per share. 
Saint-Gobain Sekurit: Plutus Wealth Management bought 5 lakh shares from the open market on January 21, 2021. With this, Plutus Wealth Management’s stakes in Saint Gobain has increased to 5.49% from 4.94%.